Skip to main content

Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study

Abstract

Introduction

In Germany, accurate data on the prevalence and treatment of osteoporosis, as well as the cost of this illness, are not available. The aim of this study is to give a valid estimation of these items for the year 2003.

Methods

Routine data from a German sickness fund covering 1.5 million beneficiaries and billing data for outpatient visits were used to obtain estimates of prevalence for osteoporosis. Claims data for patients with osteoporosis (M80, M81) or an osteoporosis-related fracture diagnosis (S22, S32, S42, S52, S72, S82) or treatment with anti-osteoporosis drugs were examined. Costs were calculated from the perspective of the German health insurance system and the German nursing care insurance system, respectively. Only direct costs of osteoporosis were considered.

Results

In 2003, 7.8 million Germans (6.5 million women) were affected by osteoporosis. Of them, 4.3% experienced at least one clinical fracture. Only 21.7% were treated with an anti-osteoporosis drug. The total direct costs attributable to osteoporosis amounted to €5.4 billion.

Conclusion

This study confirms that osteoporosis is underdiagnosed, undertreated and imposes a considerable economic burden on the health system in Germany. Effective strategies for the prevention and management of this disease are needed.

This is a preview of subscription content, access via your institution.

Fig. 1

Notes

  1. 1.

    Patients with an encounter due to Morbus Paget (ICD10: M88) and/or hypercalcaemia (ICD10: E83.5*) and/or tumour induced osteoporosis (ICD10: M90.7*) were excluded from the analysis.

References

  1. 1.

    [No authors listed] (1993) Consensus Development Conference on Osteoporosis. Hong Kong, April 1–2, 1993. Am J Med 95(5A):1S–78S

    Google Scholar 

  2. 2.

    Melton LJ (1988) Osteoporosis: etiology, diagnosis and management. In: Riggs BL, Melton LJ (eds) Epidemiology of fractures. Raven Press, New York, pp 133–154

    Google Scholar 

  3. 3.

    Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12(11):1761–1768

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27(5):585–590

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Ballard PA, Purdie DW, Langton CM, Steel SA, Mussurakis S (1998) Prevalence of osteoporosis and related risk factors in UK women in the seventh decade: osteoporosis case finding by clinical referral criteria or predictive model? Osteoporos Int 8(6):535–539

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11(7):1010–1018

    PubMed  CAS  Article  Google Scholar 

  7. 7.

    DAGO (1998) Die Empfehlungen der Deutschen Arbeitsgemeinschaft Osteoporose. Klin Pharmakol Aktuell 9:47–53

    Google Scholar 

  8. 8.

    Dewitz HD (2004) Osteoporose—Diagnostik, Prävention und Therapie. KV-Blatt 11

  9. 9.

    Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12(1):16–23

    PubMed  Article  Google Scholar 

  10. 10.

    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7(4):390–406

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Lippuner K, von Overbeck J, Perrelet R, Bosshard H, Jaeger P (1997) Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 7(5):414–425

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Glaeske G, Jahnsen K (2005) GEK—Arzneiverordnungsreport. Asgard Verlag, St. Augustin, Germany

  13. 13.

    Brecht JG, Schädlich PK (2000) Burden of illness imposed by osteoporosis in Germany. Eur J Health Econom 1(1):26–32

    Article  Google Scholar 

  14. 14.

    Rote Liste Service GmbH (2003) Rote Liste WinR. Arzneimittelverzeichnis für Deutschland. Editio Cantor Verlag, Aulendorf/Württ

  15. 15.

    DVO (2003) Osteoporose bei Frauen nach der Menopause und im höheren Lebensalter. Prophylaxe, Diagnose, Therapie—Empfehlungen des Dachverbandes der deutschsprachigen osteologischen Fachgesellschaften

  16. 16.

    AkdÄ H (2003) Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft: Osteoporose. Arzneiverordnung in der Praxis

  17. 17.

    Centers for Disease Control and Prevention (CDC) (1998) Osteoporosis among estrogen-deficient women—United States 1988–1994. Morb Mortal Wkly Rep 47(45):969–973

    Google Scholar 

  18. 18.

    Oberender PO, Fritschi DA (2003) Disease Management und Osteoporose: Versorgungsmängel bei einer relevanten Frauenkrankheit. Dtsch Ärztebl 100(25A):1728–1733

    Google Scholar 

  19. 19.

    Castel H, Bonneh DY, Sherf M, Liel Y (2001) Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int 12(7):559–564

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 82-A(8):1063–1070

    PubMed  CAS  Google Scholar 

  21. 21.

    IPSOS-SRL (2000) How fragile is her future? Osteoporosis Research in Partnership with International Osteoporosis Foundation (IOF)

  22. 22.

    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323(2):73–79

    PubMed  CAS  Article  Google Scholar 

  23. 23.

    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437–1443

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Dietrich ES, Jopp R, Schreier U, Gilge R, Bartmann P, Berthold H (2005) Drug expenditures resulting from the implementation of clinical practice guideline in Germany. Gesundh ökon Qual manag 10(1):35–43

    Article  Google Scholar 

  29. 29.

    Krappweis J, Rentsch A, Schwarz UI, Krobot KJ, Kirch W (1999) Outpatient costs of osteoporosis in a national health insurance population. Clin Ther 21(11):2001–2014

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Gotte S, Dittmar K (2001) Epidemiology and costs of osteoporosis (in German). Orthopade 30(7):402–404

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Bestehorn K, Zink A, Dreher R (2002) Drug therapy in postmenopausal osteoporosis. An analysis of healty service delivery (in German). Z Arztl Fortbild Qualitatssich 96(10):699–704

    PubMed  Google Scholar 

  32. 32.

    Gehlbach SH, Fournier M, Bigelow C (2002) Recognition of osteoporosis by primary care physicians. Am J Public Health 92(2):271–273

    PubMed  Article  Google Scholar 

  33. 33.

    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12(5):356–361

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. QJM 95(5):305–311

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13(9):731–737

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgement

This study was supported by an unrestricted grant from Hoffmann-LaRoche and GlaxoSmithKline.

Author information

Affiliations

Authors

Corresponding author

Correspondence to B. Häussler.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Häussler, B., Gothe, H., Göl, D. et al. Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. Osteoporos Int 18, 77–84 (2007). https://doi.org/10.1007/s00198-006-0206-y

Download citation

Keywords

  • Bisphosphonates
  • Costs
  • Germany
  • Osteoporosis
  • Prevalence